Drug news
SAR 153191 (sarilumab) BLA is filed at FDA to treat rheumatoid arthritis- Regeneron + Sanofi
At announcement of Q3 earnings Regeneron noted that a biologics license application (BLA) for sarilumab (SAR 153191) to treat rheumatoid arthritis was recently submitted to the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins